医学
吸入器
奇纳
科克伦图书馆
系统回顾
梅德林
成本效益
重症监护医学
慢性阻塞性肺病
物理疗法
随机对照试验
心理干预
外科
哮喘
内科学
护理部
法学
风险分析(工程)
政治学
作者
Rezwanul Hasan Rana,Khorshed Alam,Syed Afroz Keramat,Jeff Gow
标识
DOI:10.1080/17476348.2022.2145951
摘要
Evidence from non-randomized studies shows benefits for single-inhaler users compared with multiple-inhaler users who receive the same medication. As a result, comparative cost-effectiveness studies are required to inform treatment decisions with an increasing choice of medications and devices for chronic obstructive pulmonary disease (COPD). This study conducted a systematic literature review to evaluate the cost-effectiveness of using a single combination inhaler regimen for patients with severe COPD. This review also investigated the health impact on patients in different settings.A systematic literature search was conducted in PubMed (MEDLINE), EMBASE, Web of Science, Scopus, Cochrane Library, EBSCO Host (including CINAHL and EconLit), Health Technology Assessment Database, National Institute for Health Research Economic Evaluation Database, Cost-Effectiveness Analysis Registry and Google Scholar.Based on the primary findings of 13 included studies: (1) single-inhaler triple therapy was a cost-effective treatment option for patients with severe COPD, and (2) triple therapy also resulted in better health outcomes (reduced exacerbations, life-years gained) and increased QALYs for patients with severe COPD. Nonetheless, eleven out of the thirteen selected studies were funded by the pharmaceutical industry, and none were conducted in the least developed countries. Therefore, the results should be interpreted with caution.
科研通智能强力驱动
Strongly Powered by AbleSci AI